In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
William D. Tap, MD
Advertisement
Articles by William D. Tap, MD
Advertisement
Latest Updated Articles
Drug Shows 10-Month Survival Improvement in SarcomaPublished: June 7th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
3
Comprehensive Cancer Database May Enhance Personalized Therapy
4
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
5
